Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

CellAct (Commercialization and manufacturing rights to CAP7.1)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

The commercialization and manufacturing rights of an anticancer agent. The anticancer agent etoposide, which is metabolized into an active form by enzymes in the gastrointestinal tract that are particularly active in tumor cells. The drug enables the focused release of this chemotherapeutic agent into tumor cells in higher doses while maintaining a good safety and tolerability profile.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Commercial Services
Other Industries
Drug Delivery
Acquirer
Mundipharma International
Primary Office
  • BioMedizinZentrum
  • Otto-Hahn-Street 15
  • 44227 Dortmund
  • Germany

CellAct (Commercialization and manufacturing rights to CAP7.1) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore CellAct (Commercialization and manufacturing rights to CAP7.1)‘s full profile, request access.

Request full access to PitchBook

CellAct (Commercialization and manufacturing rights to CAP7.1) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore CellAct (Commercialization and manufacturing rights to CAP7.1)‘s full profile, request access.

Request full access to PitchBook